Dato-DXd (Datroway®) is a TROP2-directed ADC under investigation for multiple solid tumors, including TNBC, hormone receptor-positive (HR+) breast cancer, and NSCLC [43]. This evidence concerns the gene TACSTD2 and non-small cell lung carcinoma.